Cancer Advisor

Abstract The emergence of precision medicine has transformed cancer treatment by enabling therapies tailored to specific molecular characteristics. Personalized oncology, primarily driven by genomic and biomarker-guided interventions, has improved outcomes across multiple malignancies. However, substantial inter-patient variability in treatment response, resistance mechanisms, tumor evolution, immune interactions, and metabolic adaptations continues to challenge conventional precision oncology models. This has led to increasing interest in N=1 oncology, an individualized approach that treats each patient as a unique biological system and continuously adapts therapeutic strategies based on longitudinal clinical and molecular data. This review examines the conceptual differences between personalized oncology and N=1 oncology, explores their respective strengths and limitations, and discusses the potential role of artificial intelligence (AI), multi-omics profiling, liquid biopsy technolo...

Quick Answer: What Are the Best AI Cancer Patient Tools? The top AI cancer education and patient support tools include BelongAI (Dave) for 24/7 conversational patient guidance, Outcomes4Me for personalized NCCN treatment guideline navigation, PathologyReport.AI for decoding complex biopsy and genomic reports, and TrialJectory for AI-powered clinical trial matching. Unlike static medical search hubs like WebMD or Healthline, these specialized platforms analyze patient-specific data, medical PDFs, and disease stages to provide tailored, ad-free oncology care support. Facing a cancer diagnosis brings an overwhelming flood of complex medical jargon, pathology scans, and high-stakes treatment decisions. For decades, patients relied on search engines and generic medical reference hubs like WebMD or Healthline. However, static articles often increase anxiety rather than clarity—failing to account for a patient's exact diagnosis, biomarkers, or individual t...

Immune Checkpoint Inhibitors (ICIs)—such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies—have revolutionized oncology by releasing the molecular "brakes" on cytotoxic T-cells. However, a major clinical challenge remains: only 20% to 40% of cancer patients achieve long-term durability or complete response when treated with monotherapy. The primary barrier to response is primary or acquired resistance, driven by an immunosuppressive tumor microenvironment (TME), cold tumor phenotypes, and impaired antigen presentation. Pioneering work by researchers and authors like Dr. Justus R. Hope highlights a powerful strategy: re-sensitizing tumors to immunotherapy using low-cost, synergistic adjuncts—specifically targeted diet, repurposed medications, and natural bioactive compounds. Table of Contents 1. Tuning Up Immunotherapy with Diet & the Gut Microbiome 2. The Top 7 Repurposed Drugs in Immunotherapy Synergy 3. Most Powerful Natural Immune Boosters...

Medically Reviewed by: OneDayMD Editorial Team | Evidence Synthesis & Safety Review | Last Updated: July 2026 Quick Answer Ivermectin, fenbendazole, and mebendazole are antiparasitic drugs with laboratory evidence of anticancer activity.  The pharmacological rationale is real and merits continued, properly controlled trial investment. Patients should discuss any interest in these agents openly with their oncology team rather than self-administering veterinary or compounded formulations.  This article separates the genuine research question from the unverified claims, and outlines what to discuss with an oncology team before considering any of these agents. Background: Ivermectin and the benzimidazole anthelmintics fenbendazole and mebendazole have attracted sustained public attention as repurposed anticancer agents, driven substantially by social media case testimonials and a small number of peer-reviewed mechanistic studies. Objective: To synthesize the preclin...

Executive Summary Cancer is increasingly recognized not only as a genetic disease but also as a metabolic disease . While genetic mutations drive tumor initiation and progression, metabolic reprogramming provides the fuel that allows cancer cells to survive, adapt, evade the immune system, and resist treatment. Over the past decade, metabolic oncology has evolved from a niche research field into one of the most promising frontiers in cancer treatment. However, many discussions remain polarized. Some portray cancer as purely a metabolic disease, while others dismiss metabolic interventions altogether. The scientific evidence suggests a more nuanced reality: Cancer is simultaneously a genetic, metabolic, immunological, and ecological disease. Successful treatment often requires addressing all of these dimensions systematically. This article prese...